JAK Inhibitors, Eczema and Cardiovascular Comorbidity After Age 50

Evidence summary only; systemic treatment decisions require a prescriber.

A population often excluded from trials

A multicenter study evaluated JAK inhibitors in adults aged 50 years or older with moderate-to-severe atopic dermatitis and substantial cardiovascular comorbidity. This is clinically important because boxed warnings and baseline cardiovascular risk complicate treatment decisions.

Why real-world data help

Practice-based cohorts include polypharmacy, diabetes, hypertension, smoking history and prior cardiovascular disease more often than tightly selected trials. They can describe treatment persistence, laboratory abnormalities and events under routine monitoring.

Why reassurance must remain bounded

Clinicians may avoid JAK inhibitors in the highest-risk patients, producing channeling bias. Sample size and follow-up may be insufficient for uncommon events such as myocardial infarction, stroke, venous thrombosis or malignancy. Absence of a statistically significant signal is not proof of zero risk.

Shared benefit-risk assessment

Before treatment, clinicians may review age, smoking, prior clots, cancer history, cardiovascular disease, infection risk, vaccination and laboratory results. Alternatives, expected speed of relief and the burden of uncontrolled eczema belong in the same discussion. Risk is not determined by one factor alone.

Urgent symptoms

Chest pressure, sudden shortness of breath, facial droop, speech difficulty or a swollen painful leg requires emergency evaluation. Patients should not pause or restart a JAK inhibitor independently; the prescriber needs the full clinical context.

Bottom line

This study adds relevant evidence for a complex group. It supports careful monitoring—not blanket reassurance or blanket exclusion.

Related Dr. Arsy research

• Choosing an eczema moisturizer
• Eczema and sleep research guide
• Childhood eczema and school performance
• Comparing eczema treatments
• Targeted-therapy tapering evidence
• Recognizing eczema across skin tones

References

1. JAK inhibitors in adults with cardiovascular comorbidity
2. AAD systemic and phototherapy guideline
3. AAD topical therapy guideline
4. AAAAI/ACAAI GRADE guideline
5. Peer-led online self-management randomized trial
6. Emollient plus versus urea 10% trial
7. Upadacitinib in adults aged 60 years or older
8. Lebrikizumab in older adults real-world study
9. Tralokinumab in adults aged 70 years or older
10. Abrocitinib in elderly adults real-world study
11. Delgocitinib cream phase 2b trial
12. Ruxolitinib after topical treatment failure trial
13. Mometasone, crisaborole and tofacitinib pilot
14. CAN UpTIMISE after dupilumab study
15. DLLIM international 15,450-patient study
16. REZOLVE-AD phase 2b trial
17. Model-based meta-analysis of 77 studies
18. Targeted-therapy tapering systematic review
19. IL-4 receptor inhibitor meta-analysis
20. Dupilumab SOLO phase 3 trials
21. Tralokinumab ECZTRA 1 and 2 trials
22. Lebrikizumab ADvocate trials
23. Upadacitinib Measure Up trials
24. Abrocitinib JADE MONO-1 trial

Citations do not imply endorsement of #003.